Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06231862 · ClinicalTrials.gov registry record
Gene Expression Objective Definition of Early Sepsis In Children
A clinical trial of Sepsis and Non-Infectious Systemic Inflammatory Response Syndrome, sponsored by Seattle Children's Hospital.
- Completed
- Registry status
- 100
- Enrollment target
- 2
- Study locations
NCT06231862 is a study of Sepsis and Non-Infectious Systemic Inflammatory Response Syndrome that has completed, run by Seattle Children's Hospital. The registered enrollment target is 100 participants, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06231862, a study of Sepsis and Non-Infectious Systemic Inflammatory Response Syndrome, has completed, sponsored by Seattle Children's Hospital.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
GEODESIC is a prospective descriptive cohort investigation that will examine the generalizability of the novel host gene expression biomarkers, SeptiCyteTM LAB, SeptiCyteTM VIRUS, SeptiCyteTM BACT, and SeptiCyteTM TRIAGE (collectively 18 genes or SeptiCyteTM LVBT) and SeptiCyteTM RAPID, for differentiating children with bacterial sepsis, versus severe viral illness, versus non-infectious related systemic inflammatory response syndrome.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST SeptiCyte (various)
Study Locations (2)
Washington
- Seattle Children's Hospital, Harborview Medical Center - Seattle
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2023-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06231862
The ClinicalTrials.gov registry entry for NCT06231862 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower). The listed sponsor is Seattle Children's Hospital, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which SeptiCyte (various) is the first listed.
NCT06231862 reports 2 study locations spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT06231862 about?
NCT06231862 is a clinical study titled "Gene Expression Objective Definition of Early Sepsis In Children". GEODESIC is a prospective descriptive cohort investigation that will examine the generalizability of the novel host gene expression biomarkers, SeptiCyteTM LAB, SeptiCyteTM VIRUS, SeptiCyteTM BACT, and SeptiCyteTM TRIAGE (collectively 18 genes or SeptiCyteTM LVBT) and SeptiCyteTM RAPID, for differen...
What is the current status of trial NCT06231862?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2019-03-01. Estimated completion is 2023-03-01.
What conditions does trial NCT06231862 study?
This clinical trial studies the following conditions: Sepsis, Non-Infectious Systemic Inflammatory Response Syndrome.
What interventions are being tested in trial NCT06231862?
The interventions under investigation include: SeptiCyte (various) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06231862?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06231862 being conducted?
This trial has 2 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Explore more on PlainTrial
Sepsis
All registered trials for this condition
Non-Infectious Systemic Inflammatory Response Syndrome
All registered trials for this condition
Washington
All trials with a study site in Washington
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.